Published papers
Featured Publications
Association of Body Mass Index With Cardiometabolic Disease in the UK Biobank
Type: article, Author: Donald M. Lyall and Carlos Celis-Morales and Joey Ward, Date: 2017-07-05
Comorbidities in the diseasome are more apparent than real: What Bayesian filtering reveals about the comorbidities of depression.
Type: article, Author: P Marx and P Antal B Bolgar and G Bagdy and B Deakin and G Juhasz , Date: 2017-06-23
Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders.
Type: article, Author: A Dregan and P Chowienczyk and M Molokhia, Date: 2017-06-10
Last updated on July 7th, 2016
2017 |
María Soler Artigas Louise V. Wain, Nick Shrine Tricia McKeever UK BiLEVE Ian Sayers Ian Hall Martin Tobin M P D Targeted Sequencing of Lung Function Loci in Chronic Obstructive Pulmonary Disease Cases and Controls Journal Article In: PLOS One, 2017. Abstract | Links | BibTeX | Tags: 648, COPD, GWAS, lung function @article{Artigas2017, title = {Targeted Sequencing of Lung Function Loci in Chronic Obstructive Pulmonary Disease Cases and Controls}, author = {María Soler Artigas, Louise V. Wain , Nick Shrine, Tricia M. McKeever, UK BiLEVE , Ian Sayers, Ian P. Hall, Martin D. Tobin }, url = {http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170222}, year = {2017}, date = {2017-01-23}, journal = {PLOS One}, abstract = {Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide; smoking is the main risk factor for COPD, but genetic factors are also relevant contributors. Genome-wide association studies (GWAS) of the lung function measures used in the diagnosis of COPD have identified a number of loci, however association signals are often broad and collectively these loci only explain a small proportion of the heritability. In order to examine the association with COPD risk of genetic variants down to low allele frequencies, to aid fine-mapping of association signals and to explain more of the missing heritability, we undertook a targeted sequencing study in 300 COPD cases and 300 smoking controls for 26 loci previously reported to be associated with lung function. We used a pooled sequencing approach, with 12 pools of 25 individuals each, enabling high depth (30x) coverage per sample to be achieved. This pooled design maximised sample size and therefore power, but led to challenges during variant-calling since sequencing error rates and minor allele frequencies for rare variants can be very similar. For this reason we employed a rigorous quality control pipeline for variant detection which included the use of 3 independent calling algorithms. In order to avoid false positive associations we also developed tests to detect variants with potential batch effects and removed them before undertaking association testing. We tested for the effects of single variants and the combined effect of rare variants within a locus. We followed up the top signals with data available (only 67% of collapsing methods signals) in 4,249 COPD cases and 11,916 smoking controls from UK Biobank. We provide suggestive evidence for the combined effect of rare variants on COPD risk in TNXB and in sliding windows within MECOM and upstream of HHIP. These findings can lead to an improved understanding of the molecular pathways involved in the development of COPD}, keywords = {648, COPD, GWAS, lung function}, pubstate = {published}, tppubtype = {article} } Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide; smoking is the main risk factor for COPD, but genetic factors are also relevant contributors. Genome-wide association studies (GWAS) of the lung function measures used in the diagnosis of COPD have identified a number of loci, however association signals are often broad and collectively these loci only explain a small proportion of the heritability. In order to examine the association with COPD risk of genetic variants down to low allele frequencies, to aid fine-mapping of association signals and to explain more of the missing heritability, we undertook a targeted sequencing study in 300 COPD cases and 300 smoking controls for 26 loci previously reported to be associated with lung function. We used a pooled sequencing approach, with 12 pools of 25 individuals each, enabling high depth (30x) coverage per sample to be achieved. This pooled design maximised sample size and therefore power, but led to challenges during variant-calling since sequencing error rates and minor allele frequencies for rare variants can be very similar. For this reason we employed a rigorous quality control pipeline for variant detection which included the use of 3 independent calling algorithms. In order to avoid false positive associations we also developed tests to detect variants with potential batch effects and removed them before undertaking association testing. We tested for the effects of single variants and the combined effect of rare variants within a locus. We followed up the top signals with data available (only 67% of collapsing methods signals) in 4,249 COPD cases and 11,916 smoking controls from UK Biobank. We provide suggestive evidence for the combined effect of rare variants on COPD risk in TNXB and in sliding windows within MECOM and upstream of HHIP. These findings can lead to an improved understanding of the molecular pathways involved in the development of COPD |
2016 |
Amaral A. F. Strachan, Gomez Real Burney Jarvis D P F P G D L Lower lung function associates with cessation of menstruation: UK Biobank data Journal Article In: The European Respiratory Journal, 2016. Abstract | Links | BibTeX | Tags: lung function, menstruation @article{AmaralAF2016, title = {Lower lung function associates with cessation of menstruation: UK Biobank data}, author = {Amaral, A. F. Strachan, D. P. Gomez Real, F. Burney, P. G. Jarvis, D. L.}, url = {https://www.ncbi.nlm.nih.gov/pubmed/27660514}, year = {2016}, date = {2016-11-02}, journal = {The European Respiratory Journal}, abstract = {Little is known about the effect of cessation of menstruation on lung function. The aims of the study were to examine the association of lung function with natural and surgical cessation of menstruation, and assess whether lower lung function is associated with earlier age at cessation of menstruation.The study was performed in 141 076 women from the UK Biobank, who had provided acceptable and reproducible spirometry measurements and information on menstrual status. The associations of lung function (forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), spirometric restriction (FVC < lower limit of normal (LLN)), airflow obstruction (FEV1/FVC pubstate = {published}, tppubtype = {article} } Little is known about the effect of cessation of menstruation on lung function. The aims of the study were to examine the association of lung function with natural and surgical cessation of menstruation, and assess whether lower lung function is associated with earlier age at cessation of menstruation.The study was performed in 141 076 women from the UK Biobank, who had provided acceptable and reproducible spirometry measurements and information on menstrual status. The associations of lung function (forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), spirometric restriction (FVC < lower limit of normal (LLN)), airflow obstruction (FEV1/FVC <LLN)) with cessation of menstruation and age at cessation of menstruation were assessed using regression analysis.Women who had natural cessation of menstruation showed a lower FVC (-42 mL; 95% CI -53- -30) and FEV1 (-34 mL; 95% CI -43- -24) and higher risk of spirometric restriction (adjusted odds ratio 1.27; 95% CI 1.18-1.37) than women still menstruating. These associations were stronger in women who had had a hysterectomy and/or oophorectomy. The earlier the natural cessation of menstruation, the lower the lung function. There was no clear association of lung function with age at hysterectomy and/or oophorectomy. Airflow obstruction was not associated with cessation of menstruation.Lower lung function associates with cessation of menstruation, especially if it occurs early in life. |
2015 |
Louise V Wain PhD, Nick Shrine PhD Suzanne Miller PhD Victoria Jackson MSc Ioanna Ntalla PhD María Soler Artigas PhD Charlotte Billington PhD Abdul Kader Kheirallah BSc Richard Allen MSc James Cook PhD Kelly Probert BSc Ma'en Obeidat PhD Yohan Bossé PhD Ke Hao ScD Prof Dirkje Postma PhD Peter Paré MD Adaikalavan Ramasamy DPhil UK Brain Expression Consortium (UKBEC)† Reedik Mägi PhD Evelin Mihailov MSc Eva Reinmaa MSc Erik Melén MD Jared O'Connell DPhil Eleni Frangou MSc[Res] Olivier Delaneau PhD OxGSK Consortium† Colin Freeman PhD Desislava Petkova PhD Prof Mark McCarthy MD Ian Sayers PhD Prof Panos Deloukas PhD Prof Richard Hubbard MD Ian Pavord FMedSci Anna Hansell MBBChir Prof Neil Thomson MD Eleftheria Zeggini MD Prof Andrew Morris PhD Prof Jonathan Marchini DPhil Prof David Strachan MD* Prof Martin Tobin PhDcorrespondence*email Prof Ian Hall DM E K P S D L C P P D P In: Lancet Respiratory, 2015. Abstract | Links | BibTeX | Tags: 648, Lung Disease, lung function @article{Wain2015, title = {Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank}, author = {Louise V Wain, PhD, Nick Shrine, PhD, Suzanne Miller, PhD, Victoria E Jackson, MSc, Ioanna Ntalla, PhD, María Soler Artigas, PhD, Charlotte K Billington, PhD, Abdul Kader Kheirallah, BSc, Richard Allen, MSc, James P Cook, PhD, Kelly Probert, BSc, Ma'en Obeidat, PhD, Yohan Bossé, PhD, Ke Hao, ScD, Prof Dirkje S Postma, PhD, Peter D Paré, MD, Adaikalavan Ramasamy, DPhil, UK Brain Expression Consortium (UKBEC)†, Reedik Mägi, PhD, Evelin Mihailov, MSc, Eva Reinmaa, MSc, Erik Melén, MD, Jared O'Connell, DPhil, Eleni Frangou, MSc[Res], Olivier Delaneau, PhD, OxGSK Consortium†, Colin Freeman, PhD, Desislava Petkova, PhD, Prof Mark McCarthy, MD, Ian Sayers, PhD, Prof Panos Deloukas, PhD, Prof Richard Hubbard, MD, Ian Pavord, FMedSci, Anna L Hansell, MBBChir, Prof Neil C Thomson, MD, Eleftheria Zeggini, MD, Prof Andrew P Morris, PhD, Prof Jonathan Marchini, DPhil, Prof David P Strachan, MD*, Prof Martin D Tobin, PhDcorrespondence*email, Prof Ian P Hall, DM}, url = {http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00283-0/fulltext}, year = {2015}, date = {2015-09-28}, journal = {Lancet Respiratory}, abstract = {Background Understanding the genetic basis of airflow obstruction and smoking behaviour is key to determining the pathophysiology of chronic obstructive pulmonary disease (COPD). We used UK Biobank data to study the genetic causes of smoking behaviour and lung health. Methods We sampled individuals of European ancestry from UK Biobank, from the middle and extremes of the forced expiratory volume in 1 s (FEV1) distribution among heavy smokers (mean 35 pack-years) and never smokers. We developed a custom array for UK Biobank to provide optimum genome-wide coverage of common and low-frequency variants, dense coverage of genomic regions already implicated in lung health and disease, and to assay rare coding variants relevant to the UK population. We investigated whether there were shared genetic causes between different phenotypes defined by extremes of FEV1. We also looked for novel variants associated with extremes of FEV1 and smoking behaviour and assessed regions of the genome that had already shown evidence for a role in lung health and disease. We set genome-wide significance at p<5 × 10−8. Findings UK Biobank participants were recruited from March 15, 2006, to July 7, 2010. Sample selection for the UK BiLEVE study started on Nov 22, 2012, and was completed on Dec 20, 2012. We selected 50 008 unique samples: 10 002 individuals with low FEV1, 10 000 with average FEV1, and 5002 with high FEV1 from each of the heavy smoker and never smoker groups. We noted a substantial sharing of genetic causes of low FEV1 between heavy smokers and never smokers (p=2·29 × 10−16) and between individuals with and without doctor-diagnosed asthma (p=6·06 × 10−11). We discovered six novel genome-wide significant signals of association with extremes of FEV1, including signals at four novel loci (KANSL1, TSEN54, TET2, and RBM19/TBX5) and independent signals at two previously reported loci (NPNT and HLA-DQB1/HLA-DQA2). These variants also showed association with COPD, including in individuals with no history of smoking. The number of copies of a 150 kb region containing the 5′ end of KANSL1, a gene that is important for epigenetic gene regulation, was associated with extremes of FEV1. We also discovered five new genome-wide significant signals for smoking behaviour, including a variant in NCAM1 (chromosome 11) and a variant on chromosome 2 (between TEX41 and PABPC1P2) that has a trans effect on expression of NCAM1 in brain tissue. Interpretation By sampling from the extremes of the lung function distribution in UK Biobank, we identified novel genetic causes of lung function and smoking behaviour. These results provide new insight into the specific mechanisms underlying airflow obstruction, COPD, and tobacco addiction, and show substantial shared genetic architecture underlying airflow obstruction across individuals, irrespective of smoking behaviour and other airway disease. Funding Medical Research Council.}, keywords = {648, Lung Disease, lung function}, pubstate = {published}, tppubtype = {article} } Background Understanding the genetic basis of airflow obstruction and smoking behaviour is key to determining the pathophysiology of chronic obstructive pulmonary disease (COPD). We used UK Biobank data to study the genetic causes of smoking behaviour and lung health. Methods We sampled individuals of European ancestry from UK Biobank, from the middle and extremes of the forced expiratory volume in 1 s (FEV1) distribution among heavy smokers (mean 35 pack-years) and never smokers. We developed a custom array for UK Biobank to provide optimum genome-wide coverage of common and low-frequency variants, dense coverage of genomic regions already implicated in lung health and disease, and to assay rare coding variants relevant to the UK population. We investigated whether there were shared genetic causes between different phenotypes defined by extremes of FEV1. We also looked for novel variants associated with extremes of FEV1 and smoking behaviour and assessed regions of the genome that had already shown evidence for a role in lung health and disease. We set genome-wide significance at p<5 × 10−8. Findings UK Biobank participants were recruited from March 15, 2006, to July 7, 2010. Sample selection for the UK BiLEVE study started on Nov 22, 2012, and was completed on Dec 20, 2012. We selected 50 008 unique samples: 10 002 individuals with low FEV1, 10 000 with average FEV1, and 5002 with high FEV1 from each of the heavy smoker and never smoker groups. We noted a substantial sharing of genetic causes of low FEV1 between heavy smokers and never smokers (p=2·29 × 10−16) and between individuals with and without doctor-diagnosed asthma (p=6·06 × 10−11). We discovered six novel genome-wide significant signals of association with extremes of FEV1, including signals at four novel loci (KANSL1, TSEN54, TET2, and RBM19/TBX5) and independent signals at two previously reported loci (NPNT and HLA-DQB1/HLA-DQA2). These variants also showed association with COPD, including in individuals with no history of smoking. The number of copies of a 150 kb region containing the 5′ end of KANSL1, a gene that is important for epigenetic gene regulation, was associated with extremes of FEV1. We also discovered five new genome-wide significant signals for smoking behaviour, including a variant in NCAM1 (chromosome 11) and a variant on chromosome 2 (between TEX41 and PABPC1P2) that has a trans effect on expression of NCAM1 in brain tissue. Interpretation By sampling from the extremes of the lung function distribution in UK Biobank, we identified novel genetic causes of lung function and smoking behaviour. These results provide new insight into the specific mechanisms underlying airflow obstruction, COPD, and tobacco addiction, and show substantial shared genetic architecture underlying airflow obstruction across individuals, irrespective of smoking behaviour and other airway disease. Funding Medical Research Council. |
Miller, Suzanne; Wain, Louise; Shrine, Nick; Ntalla, Ioanna; Cook, James; Sayers, Ian; Morris, Andrew; Zeggini, Eleftheria; Marchini, Jonathan; Deloukas, Panos; Hansell, Anna; Hubbard, Richard; Pavord, Ian; Thomson, Neil; Strachan, David; Tobin, Martin; Hall, Ian 18.05.2015. Links | BibTeX | Tags: Genetic, lung function, smoking @misc{Miller2015, title = {INFLAMMATION AND COPD The Uk Bileve Study: The First Genetic Study In Uk Biobank Identifies Novel Regions Associated With Airway Obstruction And Smoking Behaviour}, author = {Suzanne Miller and Louise Wain and Nick Shrine and Ioanna Ntalla and James Cook and Ian Sayers and Andrew Morris and Eleftheria Zeggini and Jonathan Marchini and Panos Deloukas and Anna Hansell and Richard Hubbard and Ian Pavord and Neil Thomson and David Strachan and Martin Tobin and Ian Hall }, url = {http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A2714}, year = {2015}, date = {2015-05-18}, keywords = {Genetic, lung function, smoking}, pubstate = {published}, tppubtype = {presentation} } |


